Evidence map›Paper›PMID 39429470›Full record

ArticleFrontiers in oncology2024

Case report: dynamic personalized physiological monitoring in lung cancer using wearable data.

Joshua W Bliss, Whitney P Underwood, Adele M Carlson, Jessica M Scott, Robert Daly, Bob T Li, Alexander Drilon, Peter Stetson, Paul C Boutros, Lee W Jones

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua W BlissNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Whitney P UnderwoodDepartment of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Adele M CarlsonDepartment of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Jessica M ScottNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Robert DalyNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Bob T LiNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Alexander DrilonNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Peter StetsonNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States.
Lee W JonesNew York Presbyterian, Weill Cornell Medicine, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Randomized Trial of Exercise Therapy on Markers of Progression in Localized Prostate Cancer:R01CA272678 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Paul Christopher Boutros, LEE W JONES · 2022 to 2026
$3.6M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA272678
6 · The paper itself

Abstract

Pretreatment prognostication, on-treatment monitoring, and early detection of physiological symptoms are considerable challenges in cancer. We describe the feasibility of high-resolution wearable data (steps per day, walking speed) to longitudinally profile physiological trajectories extracted from Apple Health data in three patients with lung cancer from diagnosis through cancer treatment after obtaining informed consent. We used descriptive statistics to describe our approach of building longitudinal physiological profiles. The wearable data monitoring period ranged from 58 to 135 weeks, with between 34,319 and 103,535 distinct digital physiological measures collected during this period-the equivalent to 41 measures per day/patient. Longitudinal profiling revealed that wearable data accurately captured physiological changes linked with clinical events such as surgery and hospitalizations as well as initiation (and cessation) of systemic cancer treatment in all three patients. These findings suggest that wearable devices could play a critical role in the management of lung cancer, although larger studies are needed to confirm these preliminary observations and validate their generalizability. Wearable devices hold significant promise for the development of personalized "digital biomarkers," which may enhance risk stratification and management in oncology.

Indexed as

cancerexercisefunctional statuslung cancerphysiologic monitoringpreventionwearable sensors

Identifiers

PMID39429470
PMCPMC11486691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.